Multicenter, Open-label, Randomized, Uncontrolled Study to Evaluate Inhibition of Ovulation of Two Transdermal Patch Formulations Containing 0.55 mg EE and Either 1.05 or 2.1 mg GSD in Healthy Young Female Vol. Over a Period of 3 Treatment Cycles.
Phase of Trial: Phase II
Latest Information Update: 20 Dec 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 05 Jun 2009 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
- 05 Jun 2009 Planned end date changed from 1 May 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.
- 28 Jan 2009 Actual patient numbers (13) added as reported by ClinicalTrials.gov.